Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 | 9051 | 2015 |
Reduced lung-cancer mortality with volume CT screening in a randomized trial HJ de Koning, CM van Der Aalst, PA de Jong, ET Scholten, K Nackaerts, ... New England journal of medicine 382 (6), 503-513, 2020 | 2606 | 2020 |
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2561 | 2017 |
Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non–small cell lung cancer: results of the … WSME Theelen, HMU Peulen, F Lalezari, V van der Noort, JF De Vries, ... JAMA oncology 5 (9), 1276-1282, 2019 | 822 | 2019 |
Gene expression-based classification of non-small cell lung carcinomas and survival prediction J Hou, J Aerts, B Den Hamer, W Van Ijcken, M Den Bakker, P Riegman, ... PloS one 5 (4), e10312, 2010 | 798 | 2010 |
Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous … F Barlesi, A Scherpereel, A Rittmeyer, A Pazzola, N Ferrer Tur, JH Kim, ... Journal of Clinical Oncology 31 (24), 3004-3011, 2013 | 548* | 2013 |
Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer M Reck, A Luft, A Szczesna, L Havel, SW Kim, W Akerley, MC Pietanza, ... Journal of Clinical Oncology 34 (31), 3740-3748, 2016 | 540 | 2016 |
Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021 SW Hanson, C Abbafati, JG Aerts, Z Al-Aly, C Ashbaugh, T Ballouz, ... Jama 328 (16), 1604-1615, 2022 | 535 | 2022 |
PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced … S Senan, A Brade, L Wang, J Vansteenkiste, S Dakhil, B Biesma, ... Journal of clinical oncology 34 (9), 953-962, 2016 | 495 | 2016 |
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled … M Maio, A Scherpereel, L Calabrò, J Aerts, SC Perez, A Bearz, ... The Lancet Oncology 18 (9), 1261-1273, 2017 | 439 | 2017 |
The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes F Dammeijer, M van Gulijk, EE Mulder, M Lukkes, L Klaase, ... Cancer cell 38 (5), 685-700. e8, 2020 | 428 | 2020 |
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials WSME Theelen, D Chen, V Verma, BP Hobbs, HMU Peulen, JGJV Aerts, ... The Lancet Respiratory Medicine 9 (5), 467-475, 2021 | 398 | 2021 |
Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial S Uzun, RS Djamin, JAJW Kluytmans, PGH Mulder, NE van't Veer, ... The Lancet Respiratory Medicine 2 (5), 361-368, 2014 | 375 | 2014 |
Novel insights into mesothelioma biology and implications for therapy TA Yap, JG Aerts, S Popat, DA Fennell Nature Reviews Cancer 17 (8), 475-488, 2017 | 341 | 2017 |
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function JD Veltman, MEH Lambers, M van Nimwegen, RW Hendriks, ... BMC cancer 10, 1-13, 2010 | 327 | 2010 |
Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial N Horeweg, CM Van Der Aalst, E Thunnissen, K Nackaerts, C Weenink, ... American journal of respiratory and critical care medicine 187 (8), 848-854, 2013 | 302 | 2013 |
Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the … F Barlesi, A Scherpereel, V Gorbunova, R Gervais, A Vikström, C Chouaid, ... Annals of oncology 25 (5), 1044-1052, 2014 | 216 | 2014 |
Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma JP Hegmans, JD Veltman, ME Lambers, IJM de Vries, CG Figdor, ... American journal of respiratory and critical care medicine 181 (12), 1383-1390, 2010 | 189 | 2010 |
Tumor-specific cytotoxic T cells are crucial for efficacy of immunomodulatory antibodies in patients with lung cancer JG Aerts, JP Hegmans Cancer research 73 (8), 2381-2388, 2013 | 188 | 2013 |
IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain N Nogami, F Barlesi, MA Socinski, M Reck, CA Thomas, F Cappuzzo, ... Journal of Thoracic Oncology 17 (2), 309-323, 2022 | 186 | 2022 |